First-in-human dose-escalation study of the selective EGFR/HER2 exon 20 inhibitor PFL-721 in patients with locally advanced or metastatic NSCLC.

8619 Background: PFL-721 is a highly selective, orally bioavailable tyrosine kinase inhibitor (TKI) targeting activating EGFR 480 mg QD, n=1, 600 mg QD, n=1), grade 3 fatigue (600 mg QD, n=1), and grade 4 hypokalemia (600 mg QD, n=1). PK analyses showed dose-proportional exposure and achievement of plasma concentrations predicted to be effective based on preclinical models, at doses of ≥240 mg QD. Among efficacy population (n=42), partial responses (PRs) were observed in 15 / 28 pts at doses of ≥360 mg QD . The overall response and disease control rates at doses ≥360 mg QD were 54% (95%CI 33. 9-72.5) and 79% (95%CI 59.0-97.7), respectively. Among 25 evaluable pts, molecular responses (ctDNA decrease >50%) were observed in 12 at doses ≥120 mg. Conclusions: In this dose escalation study, class-effect local gastrointestinal AEs were observed in nearly all pts while the frequency of systemic skin toxicity was low, in line with the selectivity of the molecule for mutant EGFR. Antitumor activity was reported in 54% of pts at doses ≥360 mg QD in a heavily pretreated population, including with prior EGFR/ERBB2 ex20 TKI. Consistent with tumor shrinkage, ctDNA clearance was observed in 48% of evaluable pts. The randomized dose-optimization part is ongoing, with three dose regimens: 360 mg QD, 480 mg QD, and 240 mg BID. Clinical trial information: NCT06043817 .